Drug Profile
Research programme: diabetes/obesity therapy - Azign Bioscience
Alternative Names: diabetes/obesity research programme - Azign BioscienceLatest Information Update: 25 Feb 2004
Price :
$50
*
At a glance
- Originator Azign Bioscience
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus; Obesity
Most Recent Events
- 25 Feb 2004 Discontinued - Preclinical for Diabetes mellitus in Denmark (unspecified route)
- 25 Feb 2004 Discontinued - Preclinical for Obesity in Denmark (unspecified route)
- 25 Aug 2003 No development reported - Preclinical for Diabetes mellitus in Denmark (unspecified route)